Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy

被引：0
|
作者：
Lee, J. H. [1 ]
Lim, S. Y. [2 ]
Menzies, A. M. [3 ,4 ]
Carlino, M. S. [5 ]
Guminski, A. [3 ,4 ]
Nahar, K. [6 ]
Palmieri, D. [7 ]
Breen, E. [2 ]
Kefford, R. [8 ,9 ]
Scolyer, R. [10 ]
Long, G. V. [3 ,4 ]
Rizos, H. [1 ]
机构：
[1] Macquarie Univ, Melanoma Inst Australia, Biomed Sci, Sydney, NSW, Australia
[2] Macquarie Univ, Biomed Sci, Sydney, NSW, Australia
[3] Univ Sydney, Royal North Shore Hosp, Melanoma Inst Australia, Dept Med Oncol, Sydney, NSW, Australia
[4] Univ Sydney, Mater Hosp, Melanoma Inst Australia, Dept Med Oncol, Sydney, NSW, Australia
[5] Univ Sydney, Melanoma Inst Australia, Crown Princess Mary Canc Ctr, Med Oncol, Westmead, NSW, Australia
[6] Univ Sydney, Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia
[7] Crown Princess Mary Canc Ctr, Med Oncol, Westmead, NSW, Australia
[8] Macquarie Univ, Clin Med, Sydney, NSW, Australia
[9] Univ Sydney, Westmead Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[10] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Pathol, Camperdown, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
基金：
英国医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1861P
引用
收藏
页码：659 / 659
页数：1
相关论文
共 50 条
  • [1] Response assessment to anti-CTLA4 or/and anti-PD1 immunotherapy in mucosal melanomas
    Moya-Plana, Antoine
    Herrera-Gomez, Ruth Gabriela
    Rossoni, Caroline
    Dercle, Laurent
    Ammari, Samy
    Girault, Isabelle
    Roy, Severine
    Scoazec, Jean-Yves
    Vagner, Stephan
    Janot, Francois
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo
    Das, Rituparna
    Verma, Rakesh
    Sznol, Mario
    Boddupalli, Chadra Sekhar
    Gettinger, Scott
    Kluger, Harriet
    Dhodapkar, Madhav
    Dhodapkar, Kavita
    CANCER RESEARCH, 2015, 75
  • [3] Neoadjuvant anti-CTLA4 and anti-PD1 blockade in advanced urothelial cancer
    Tregunna R.
    Nature Reviews Urology, 2020, 17 (12) : 658 - 658
  • [4] Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
    Shklovskaya, Elena
    Pedersen, Bernadette
    Stewart, Ashleigh
    Simpson, Jack O. G.
    Ming, Zizhen
    Irvine, Mal
    Scolyer, Richard A.
    Long, Georgina, V
    Rizos, Helen
    CANCERS, 2022, 14 (19)
  • [5] Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy
    Dearden, Helen Clare
    Au, Lewis
    Wang, Daniel Ying
    Zimmer, Lisa
    Eroglu, Zeynep
    Smith, Jessica Louise
    Curvietto, Marcello
    Khoo, Chloe
    Atkinson, Victoria
    Lo, Serigne
    Guminski, Alexander
    Long, Georgina V.
    Sandhu, Shahneen Kaur
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Johnson, Douglas Buckner
    Larkin, James M. G.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Enhancement of anti-PD1 and anti-CTLA4 efficacy by NBTXR3 nanoparticles exposed to radiotherapy
    Hu, Yun
    Zhang, Ping
    Darmon, Audrey
    Cortez, Maria Angelica
    Paris, Sebastien
    Welsh, James
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit
    Patel, Anisha B.
    Farooq, Sahira
    Welborn, Macartney
    Amaria, Rodabe N.
    Chon, Susan Y.
    Diab, Adi
    Oliva, Isabella C. Glitza
    Huen, Auris O.
    Li, Shirley Q.
    Nelson, Kelly C.
    Pacha, Omar
    Patel, Sapna P.
    Rapini, Ronald P.
    Tawbi, Hussein A.
    Wong, Michael K.
    McQuade, Jennifer
    Davies, Michael A.
    Haydu, Lauren E.
    CANCER, 2022, 128 (05) : 975 - 983
  • [8] The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China A bibliometrics study
    Zhao, Xiaoqin
    He, Liangmei
    Mao, Kaiyun
    Chen, Daming
    Jiang, Hongbo
    Liu, Zhiping
    MEDICINE, 2018, 97 (15)
  • [9] Original Research Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
    Dearden, Helen
    Au, Lewis
    Wang, Daniel Y.
    Zimmer, Lisa
    Eroglu, Zeynep
    Smith, Jessica L.
    Cuvietto, Marcello
    Khoo, Chloe
    Atkinson, Victoria
    Lo, Serigne
    V. Long, Georgina
    Sandhu, Shahneen
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Johnson, Douglas B.
    Larkin, James
    Menzies, Alexander M.
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 168 - 178
  • [10] Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy
    Godse, R.
    Mcgettigan, S.
    Schuchter, L. M.
    Ellebrecht, C. T.
    Chu, E. Y.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021, 46 (06) : 1111 - +
12345